Skip to main content
Selvita S.A. logo

Selvita S.A. — Investor Relations & Filings

Ticker · SLV ISIN · PLSLVCR00029 LEI · 25940057WQ9YP5MOQF28 WAR Professional, scientific and technical activities
Open in API
Filings indexed 1,179 across all filing types
Latest filing 2021-06-30 Regulatory Filings
Country PL Poland
Listing WAR SLV

About Selvita S.A.

https://selvita.com/

Selvita S.A. is a preclinical contract research organization (CRO) providing integrated services for the pharmaceutical and biotechnology sectors. The company offers comprehensive solutions across the drug discovery and development continuum, from target validation to preclinical candidate nomination. Core drug discovery capabilities include medicinal chemistry, pharmacology, DMPK, and protein sciences, supporting a wide range of modalities such as small molecules, antibodies, and protein degraders. For drug development, Selvita provides analytical support for small and large molecules, formulation, microbiology services, and manufacturing for clinical trials. The company operates under GMP and GLP quality standards, offering flexible engagement models that range from standalone studies to fully integrated programs.

Recent filings

Filing Released Lang Actions
Zawarcie znaczącej umowy - Content (EN)
Regulatory Filings Classification · 95% confidence The document describes the conclusion of a significant agreement between an affiliated company (Selvita Inc.) and the University of California San Francisco (UCSF) for drug discovery services, detailing the value ($4.183 million) and duration (36 months). This type of announcement, concerning a major contract or business development that is not a standard financial report (like 10-K or IR) or a management change, typically falls under general regulatory announcements or significant business updates. Since there is no specific category for 'Major Contract Award' and it is a formal disclosure, it best fits the 'Regulatory Filings' (RNS) fallback category, as it is a material event disclosure.
2021-06-30 English
Zawarcie znaczącej umowy - Content (PL)
Regulatory Filings Classification · 100% confidence The document text is in Polish and describes a contract agreement ('Umowa') signed between a subsidiary of Selvita S.A. and the University of California, San Francisco (UCSF). The contract is valued at USD 4,183,200 and concerns research support in medicinal chemistry. The text explicitly states that the Management Board ('Zarząd Emitenta') considers the Agreement significant due to its value and the extension of cooperation with a key client. This type of announcement, detailing a significant business contract or transaction that impacts the company's operations or financial outlook, typically falls under general regulatory announcements or specific transaction reporting. Since there is no specific category for 'Contract Signing' and it is not a standard financial report (10-K, IR, ER), nor a management change (MANG) or director dealing (DIRS), it is best classified as a general Regulatory Filing (RNS) or potentially a transaction/material event disclosure. Given the context of reporting material events that aren't explicitly covered elsewhere, RNS is the most appropriate fallback. The document length is very short (1160 chars), suggesting it is an announcement rather than a full report.
2021-06-30 Polish
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Zwyczajnym Walnym Zgromadzeniu Selvita S.A. w dniu 29 czerwca 2021 r. / Shareholders controlling at least 5% of the votes at the Ge...
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states that the Management Board is announcing the list of shareholders who held at least 5% of the votes at the General Meeting (Zwyczajnym Walnym Zgromadzeniu Spółki - WZ) held on June 30, 2021. This content details the results of voting rights distribution and shareholder representation from a general meeting. This directly aligns with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes at any general meeting.
2021-06-30 Polish
Protokół notarialny_ZWZ Selvita SA_2021.06.29
AGM Information Classification · 100% confidence The document text is explicitly titled "PROTOKÓŁ Z ZWYCZAJNEGO WALNEGO ZGROMADZENIA SELVITA S.A." (Minutes of the Annual General Meeting of SELVITA S.A.). It details the proceedings, voting on resolutions (Uchwała Nr 1 through Nr 6), the election of the Chairman, the establishment of the Scrutiny Committee, and the approval of annual reports and profit distribution for the fiscal year 2020. This content perfectly matches the definition of materials shared during an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2021-06-30 Polish
Treść uchwał podjętych przez Zwyczajne Walne Zgromadzenie Selvita S.A. / Resolutions adopted by the General Shareholders Meeting of Selvita S.A. - Content (PL)
AGM Information Classification · 98% confidence The document explicitly states that the Management Board is 'przekazuje w załączeniu treść uchwał podjętych przez Zwyczajne Walne Zgromadzenie Emitenta' (informs about the resolutions adopted by the General Shareholders Meeting) and details the voting results (votes 'in favor', 'against', 'abstentions'). This content directly relates to the official results from a shareholder vote at a general meeting. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA). The document is short and reports the results, not just announcing that results are available elsewhere.
2021-06-30 Polish
Otrzymanie znaczącego zlecenia / Receipt of a significant purchase order - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a formal announcement by the Management Board of Selvita S.A. (the Issuer) regarding the receipt of a significant Purchase Order (Zlecenie) from a US-based client for chemical synthesis services. This announcement details the value ($1.02M), the duration (July 1, 2021, to June 30, 2022), and the nature of the contract (drug discovery services). This type of disclosure, concerning a material contract or transaction that is not a standard periodic financial report (like 10-K or IR) or a change in management/board, typically falls under general regulatory disclosures. Since it is a specific announcement about a material contract/transaction, it is best classified as a general Regulatory Filing (RNS) as it doesn't fit the specific categories like CAP (financing), MANG (management change), or LTR (legal proceedings). Given the context of Polish/EU regulatory filings, this is a standard material event disclosure.
2021-06-28 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.